Pegbio is a Suzhou-based biopharmaceutical company focusing on developing innovative therapies for diabetes and obesity. The company announced it secured around 800 million yuan (about $122 million) in a pre-IPO financing. The round was co-led by Jack Ma’s YF Capital, private equity firm Yingke PE, and life sciences-focused investor TF Capital. The article does not disclose a valuation, specific deal terms, or operational metrics such as revenue or user counts. No details on prior funding rounds or intended use of proceeds were provided in the coverage.

Total raised

$122M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2020